Seattle firm Presage Biosciences has secured $6m in investment from Japanese pharma firm Takeda and US biopharma outfit Celgene . The money will be used to expand the use of Presage 's Presage platform, which tests microscopic amounts of drugs in cancer patients to determine their effects, ahead of phase I trials. The platform is capable of providing faster proof-of-concept studies for early-stage drug candidates, he added. In addition, the company also revealed CSO Nathan Caffo had been appointed CEO, replacing Richard Klinghoffer , who will take on an advisory position.
Seattle firm Presage Biosciences has secured $6m in investment from Japanese pharma firm Takeda and US biopharma outfit Celgene . The money will be used to expand the use of Presage 's Presage platform, which tests microscopic amounts of drugs in cancer patients to determine their effects, ahead of phase I trials. In addition, the company also revealed CSO Nathan Caffo had been appointed CEO, replacing Richard Klinghoffer , who will take on an advisory position.